{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:34:35Z","timestamp":1778589275918,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/01585"],"award-info":[{"award-number":["PI22\/01585"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00987"],"award-info":[{"award-number":["PI20\/00987"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-026-01637-7","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:30:19Z","timestamp":1775007019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment"],"prefix":"10.1186","volume":"18","author":[{"given":"Ilaria","family":"Priano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Amat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Carbonell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aina","family":"Arbus\u00e0-Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Iranzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Soleda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Romero-Sola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Sinigaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Polo-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Callejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Valdivia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Hernandez-Losa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Sese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriol","family":"Mirallas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Masfarr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Cedr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Martinez-Marti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8562-6132","authenticated-orcid":false,"given":"Roc\u00edo","family":"Caro-Consuegra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-0098","authenticated-orcid":false,"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"1637_CR1","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG, Diehn M, Andr\u00e9 F, Roy-Chowdhuri S, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024;187:1617\u201335. https:\/\/doi.org\/10.1016\/j.cell.2024.02.041.","journal-title":"Cell"},{"key":"1637_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:358\u201376. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.013.","journal-title":"Ann Oncol"},{"key":"1637_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-line immunotherapy for non\u2013small-cell lung cancer. J Clin Oncol. 2022;40:586\u201397. https:\/\/doi.org\/10.1200\/JCO.21.01497.","journal-title":"J Clin Oncol"},{"key":"1637_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847\u201356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983.","journal-title":"Mol Cancer Ther"},{"key":"1637_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202\u20136. https:\/\/doi.org\/10.1038\/s41588-018-0312-8.","journal-title":"Nat Genet"},{"key":"1637_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Sci (80-). 2015;348:124\u20138. https:\/\/doi.org\/10.1126\/science.aaa1348.","journal-title":"Sci (80-)"},{"key":"1637_CR7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular determinants of response to anti\u2013programmed cell death (PD)-1 and Anti\u2013programmed death-ligand 1 (PD-L1) blockade in patients with non\u2013small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36:633\u201341. https:\/\/doi.org\/10.1200\/JCO.2017.75.3384.","journal-title":"J Clin Oncol"},{"key":"1637_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 2018;33:843\u2013e8524. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.018.","journal-title":"Cancer Cell"},{"key":"1637_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/1878-0261.12891","volume":"15","author":"J Frigola","year":"2021","unstructured":"Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedr\u00e9s S, et al. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non\u2010small cell lung cancer. Mol Oncol. 2021;15:887\u2013900. https:\/\/doi.org\/10.1002\/1878-0261.12891.","journal-title":"Mol Oncol"},{"key":"1637_CR10","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.jtho.2019.08.427","volume":"14","author":"M Garassino","year":"2019","unstructured":"Garassino M, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, Speranza G, et al. OA04.06 evaluation of TMB in KEYNOTE-189: pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC. J Thorac Oncol. 2019;14:S216\u20137. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.427.","journal-title":"J Thorac Oncol"},{"key":"1637_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jtho.2023.01.091","volume":"18","author":"JV Alessi","year":"2023","unstructured":"Alessi JV, Elkrief A, Ricciuti B, Wang X, Cortellini A, Vaz VR, et al. Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC. J Thorac Oncol. 2023;18:731\u201343. https:\/\/doi.org\/10.1016\/j.jtho.2023.01.091.","journal-title":"J Thorac Oncol"},{"key":"1637_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41467-023-36328-z","volume":"14","author":"L Hong","year":"2023","unstructured":"Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, et al. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun. 2023;14:695. https:\/\/doi.org\/10.1038\/s41467-023-36328-z.","journal-title":"Nat Commun"},{"key":"1637_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41576-019-0171-x","volume":"21","author":"U Ben-David","year":"2020","unstructured":"Ben-David U, Amon A. Context is everything: aneuploidy in cancer. Nat Rev Genet. 2020;21:44\u201362. https:\/\/doi.org\/10.1038\/s41576-019-0171-x.","journal-title":"Nat Rev Genet"},{"key":"1637_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018;33:676\u2013e6893. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.007.","journal-title":"Cancer Cell"},{"key":"1637_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1126\/science.aaf8399","volume":"355","author":"T Davoli","year":"2017","unstructured":"Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Sci (80-). 2017;355:355. https:\/\/doi.org\/10.1126\/science.aaf8399.","journal-title":"Sci (80-)"},{"key":"1637_CR16","doi-asserted-by":"publisher","unstructured":"Roh W, Chen P-L, Reuben A, Spencer CN, Prieto PA, Miller JP, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9. https:\/\/doi.org\/10.1126\/scitranslmed.aah3560.","DOI":"10.1126\/scitranslmed.aah3560"},{"key":"1637_CR17","doi-asserted-by":"publisher","first-page":"e004197","DOI":"10.1136\/jitc-2021-004197","volume":"10","author":"J Frigola","year":"2022","unstructured":"Frigola J, Carbonell C, Iranzo P, Pardo N, Callejo A, Cedres S, et al. High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. J Immunother Cancer. 2022;10:e004197. https:\/\/doi.org\/10.1136\/jitc-2021-004197.","journal-title":"J Immunother Cancer"},{"key":"1637_CR18","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jtho.2023.05.019","volume":"18","author":"JV Alessi","year":"2023","unstructured":"Alessi JV, Wang X, Elkrief A, Ricciuti B, Li YY, Gupta H, et al. Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in NSCLC. J Thorac Oncol. 2023;18:1524\u201337. https:\/\/doi.org\/10.1016\/j.jtho.2023.05.019.","journal-title":"J Thorac Oncol"},{"key":"1637_CR19","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1158\/1078-0432.CCR-18-1940","volume":"25","author":"C Richard","year":"2019","unstructured":"Richard C, Fumet J-D, Chevrier S, Derang\u00e8re V, Ledys F, Lagrange A, et al. Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients. Clin Cancer Res. 2019;25:957\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1940.","journal-title":"Clin Cancer Res"},{"key":"1637_CR20","doi-asserted-by":"publisher","first-page":"e000374","DOI":"10.1136\/jitc-2019-000374","volume":"8","author":"Z Lu","year":"2020","unstructured":"Lu Z, Chen H, Li S, Gong J, Li J, Zou J, et al. Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. J Immunother Cancer. 2020;8:e000374. https:\/\/doi.org\/10.1136\/jitc-2019-000374.","journal-title":"J Immunother Cancer"},{"key":"1637_CR21","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-19-0558","volume":"25","author":"L Liu","year":"2019","unstructured":"Liu L, Bai X, Wang J, Tang X-R, Wu D-H, Du S-S, et al. Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer. Clin Cancer Res. 2019;25:7413\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0558.","journal-title":"Clin Cancer Res"},{"key":"1637_CR22","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41588-022-01235-4","volume":"54","author":"LF Spurr","year":"2022","unstructured":"Spurr LF, Weichselbaum RR, Pitroda SP. Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2022;54:1782\u20135. https:\/\/doi.org\/10.1038\/s41588-022-01235-4.","journal-title":"Nat Genet"},{"key":"1637_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1637_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/NARGAB\/LQAE031","volume":"6","author":"F Hanssen","year":"2024","unstructured":"Hanssen F, Garcia MU, Folkersen L, Pedersen AS, Lescai F, Jodoin S, et al. Scalable and efficient DNA sequencing analysis on different compute infrastructures aiding variant discovery. NAR Genomics Bioinforma. 2024;6:31. https:\/\/doi.org\/10.1093\/NARGAB\/LQAE031.","journal-title":"NAR Genomics Bioinforma"},{"key":"1637_CR25","doi-asserted-by":"publisher","unstructured":"Garcia M, Juhos S, Larsson M, Olason PI, Martin M, Eisfeldt J et al. Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Research 2020 963. 2020;9:63. https:\/\/doi.org\/10.12688\/f1000research.16665.2.","DOI":"10.12688\/f1000research.16665.2"},{"key":"1637_CR26","unstructured":"Picard Toolkit. Broad Institute, Github repository. 2019. https:\/\/github.com\/broadinstitute\/picard. Accessed 27 Oct 2025."},{"key":"1637_CR27","doi-asserted-by":"publisher","unstructured":"Lai D, Ha G, Shah S, HMMcopy. Copy number prediction with correction for GC and mappability bias for HTS data. 2025. https:\/\/doi.org\/10.18129\/B9.bioc.HMMcopy.","DOI":"10.18129\/B9.bioc.HMMcopy"},{"key":"1637_CR28","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324. https:\/\/doi.org\/10.1038\/s41467-017-00965-y.","journal-title":"Nat Commun"},{"key":"1637_CR29","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41. https:\/\/doi.org\/10.1186\/gb-2011-12-4-r41.","journal-title":"Genome Biol"},{"key":"1637_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173:291\u2013e3046. https:\/\/doi.org\/10.1016\/j.cell.2018.03.022.","journal-title":"Cell"},{"key":"1637_CR31","doi-asserted-by":"publisher","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6. https:\/\/doi.org\/10.1126\/scisignal.2004088.","DOI":"10.1126\/scisignal.2004088"},{"key":"1637_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095.","journal-title":"Cancer Discov"},{"key":"1637_CR33","doi-asserted-by":"publisher","unstructured":"Broad Institute TCGA Genome Data Analysis Center. (2016): LowPass Copy number analysis (GISTIC2). Broad Institute of MIT and Harvard. 2016. https:\/\/doi.org\/10.7908\/C1GB23FP.","DOI":"10.7908\/C1GB23FP"},{"key":"1637_CR34","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.21105\/JOSS.01317","volume":"4","author":"C Davidson-Pilon","year":"2019","unstructured":"Davidson-Pilon C. lifelines: survival analysis in Python. J Open Source Softw. 2019;4:1317. https:\/\/doi.org\/10.21105\/JOSS.01317.","journal-title":"J Open Source Softw"},{"key":"1637_CR35","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, et al. The immune landscape of cancer. Immunity. 2018;48:812\u2013e83014. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023.","journal-title":"Immunity"},{"key":"1637_CR36","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782\u201395. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.003.","journal-title":"Immunity"},{"key":"1637_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen B, Fong C, Luthra A, Smith SA, DiNatale RG, Nandakumar S, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022;185:563\u2013e57511. https:\/\/doi.org\/10.1016\/j.cell.2022.01.003.","journal-title":"Cell"},{"key":"1637_CR38","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jtho.2024.12.020","volume":"20","author":"X Zhao","year":"2025","unstructured":"Zhao X, Liu B, William WN, Tsanov KM, Ho Y-J, Barriga FM, et al. Interferon epsilon loss is elusive 9p21 link to immune-cold tumors, resistant to immune checkpoint therapy, and endogenous CXCL9\/10 induction. J Thorac Oncol. 2025;20:1177\u2013236. https:\/\/doi.org\/10.1016\/j.jtho.2024.12.020.","journal-title":"J Thorac Oncol"},{"key":"1637_CR39","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021;12:5606. https:\/\/doi.org\/10.1038\/s41467-021-25894-9.","journal-title":"Nat Commun"},{"key":"1637_CR40","doi-asserted-by":"publisher","first-page":"9693","DOI":"10.1136\/JITC-2024-009693","volume":"12","author":"H Li","year":"2024","unstructured":"Li H, Liu J, Zhang L, Xu Y, Wang X, Lan S, et al. Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC. J Immunother Cancer. 2024;12:9693. https:\/\/doi.org\/10.1136\/JITC-2024-009693.","journal-title":"J Immunother Cancer"},{"key":"1637_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41576-024-00761-7","volume":"26","author":"X Chen","year":"2025","unstructured":"Chen X, Agustinus AS, Li J, DiBona M, Bakhoum SF. Chromosomal instability as a driver of cancer progression. Nat Rev Genet. 2025;26:31\u201346. https:\/\/doi.org\/10.1038\/s41576-024-00761-7.","journal-title":"Nat Rev Genet"},{"key":"1637_CR42","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA class i antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7:1420\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0593.","journal-title":"Cancer Discov"},{"key":"1637_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025;25:353\u201369. https:\/\/doi.org\/10.1038\/s41577-024-01111-8.","journal-title":"Nat Rev Immunol"},{"key":"1637_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37:443\u201355. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.017.","journal-title":"Cancer Cell"},{"key":"1637_CR45","doi-asserted-by":"publisher","first-page":"8671","DOI":"10.1073\/PNAS.0811835106","volume":"106","author":"C Swanton","year":"2009","unstructured":"Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, et al. Chromosomal instability determines taxane response. Proc Natl Acad Sci. 2009;106:8671\u20136. https:\/\/doi.org\/10.1073\/PNAS.0811835106.","journal-title":"Proc Natl Acad Sci"},{"key":"1637_CR46","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.4161\/CC.8.20.9690","volume":"8","author":"SE McClelland","year":"2009","unstructured":"McClelland SE, Burrell RA, Swanton C. Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle. 2009;8:3262\u20136. https:\/\/doi.org\/10.4161\/CC.8.20.9690.","journal-title":"Cell Cycle"},{"key":"1637_CR47","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41588-025-02233-y","volume":"57","author":"JS Thompson","year":"2025","unstructured":"Thompson JS, Madrid L, Hernando B, Sauer CM, Vias M, Escobar-Rey M, et al. Predicting resistance to chemotherapy using chromosomal instability signatures. Nat Genet. 2025;57:1708\u201317. https:\/\/doi.org\/10.1038\/s41588-025-02233-y.","journal-title":"Nat Genet"},{"key":"1637_CR48","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1038\/s41467-018-06567-6","volume":"9","author":"D Smeets","year":"2018","unstructured":"Smeets D, Miller IS, O\u2019Connor DP, Das S, Moran B, Boeckx B, et al. Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nat Commun. 2018;9:4112. https:\/\/doi.org\/10.1038\/s41467-018-06567-6.","journal-title":"Nat Commun"},{"key":"1637_CR49","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa1716948.","journal-title":"N Engl J Med"},{"key":"1637_CR50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41698-022-00286-4","volume":"6","author":"EM Ebot","year":"2022","unstructured":"Ebot EM, Duncan DL, Tolba K, Fabrizio D, Frampton GM, Comment LA, et al. Deletions on 9p21 are associated with worse outcomes after anti-PD-1\/PD-L1 monotherapy but not chemoimmunotherapy. npj Precis Oncol. 2022;6:44. https:\/\/doi.org\/10.1038\/s41698-022-00286-4.","journal-title":"npj Precis Oncol"},{"key":"1637_CR51","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s43018-022-00443-5","volume":"3","author":"FM Barriga","year":"2022","unstructured":"Barriga FM, Tsanov KM, Ho YJ, Sohail N, Zhang A, Baslan T, et al. MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nat Cancer 2022 311. 2022;3:1367\u201385. https:\/\/doi.org\/10.1038\/s43018-022-00443-5.","journal-title":"Nat Cancer 2022 311"},{"key":"1637_CR52","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/35096061","volume":"2","author":"CJ Sherr","year":"2001","unstructured":"Sherr CJ. The INK4a\/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001 210. 2001;2:731\u20137. https:\/\/doi.org\/10.1038\/35096061.","journal-title":"Nat Rev Mol Cell Biol 2001 210"},{"key":"1637_CR53","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.annonc.2020.02.017","volume":"31","author":"G Lamberti","year":"2020","unstructured":"Lamberti G, Spurr LF, Li Y, Ricciuti B, Recondo G, Umeton R, et al. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020;31:807\u201314. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.017.","journal-title":"Ann Oncol"},{"key":"1637_CR54","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","volume":"55","author":"A Ravi","year":"2023","unstructured":"Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet. 2023;55:807\u201319. https:\/\/doi.org\/10.1038\/s41588-023-01355-5.","journal-title":"Nat Genet"},{"key":"1637_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2019.08.001","volume":"120","author":"HS Kim","year":"2019","unstructured":"Kim HS, Cha H, Kim J, Park W-Y, Choi Y-L, Sun J-M, et al. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. Eur J Cancer. 2019;120:65\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.001.","journal-title":"Eur J Cancer"},{"key":"1637_CR56","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","volume":"52","author":"I Cort\u00e9s-Ciriano","year":"2020","unstructured":"Cort\u00e9s-Ciriano I, Lee JJ-K, Xi R, Jain D, Jung YL, Yang L, et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2020;52:331\u201341. https:\/\/doi.org\/10.1038\/s41588-019-0576-7.","journal-title":"Nat Genet"},{"key":"1637_CR57","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018;33:676\u2013e6893. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.007.","journal-title":"Cancer Cell"},{"key":"1637_CR58","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41576-022-00521-5","volume":"23","author":"E Yi","year":"2022","unstructured":"Yi E, Chamorro Gonz\u00e1lez R, Henssen AG, Verhaak RGW. Extrachromosomal DNA amplifications in cancer. Nat Rev Genet. 2022;23:760\u201371. https:\/\/doi.org\/10.1038\/s41576-022-00521-5.","journal-title":"Nat Rev Genet"},{"key":"1637_CR59","doi-asserted-by":"crossref","unstructured":"Priano I, Amat R, Carbonell C, Arbus\u00e0-Roca A, Iranzo P, Pardo N et al. Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment. Dataset ID: EGAD50000002322. European Genome-Phenome Archive (EGA). 2026. https:\/\/ega-archive.org\/datasets\/EGAD50000002322.","DOI":"10.1186\/s13073-026-01637-7"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01637-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01637-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01637-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:45:02Z","timestamp":1778546702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01637-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01637-7","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and was approved by the Hospital Institutional Review Board (PR(AG)525\/2022). All living participants provided informed consent to participate in the study. For deceased patients, their participation was approved by the mentioned review board under an amendment that waived the need for informed consent, in accordance with Article 58.2 of the Spanish Biomedical Research Law (Ley 14\/2007). The study methodologies conformed to the standards set by the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E.F. reports receiving honoraria and\/or consulting fees: Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Ellipses Pharma, Gilead, Glaxo Smith Kline, Genentech \/ Roche, ITEOS, Janssen \/ Johnson & Johnson, Medical Trends, Medscape, Moderna, MSD, Pfizer, Regeneron, Pierre Fabre, Peervoice, Pharmamar, Seagen, Tubulis GmbH. Grifols (independent board member). Support for meeting attendance and\/or travel: Amgen, AstraZeneca, Johnson & Johnson, Roche. Moreover, she is a member of the Scientific Advisory Committee at Hospital Universitari Parc Taul\u00ed, former President of SEOM (Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica, 2021-2023), and Member of the ETOP IBCSG Partners Scientific Committee. R.A. and C.C. are current employees of AstraZeneca. P.I. reports receiving consulting fees from Boehringer. Honoraria from: AstraZeneca, Regeneron, Janssen, Pfizer, Takeda. Support for attending meetings and\/or travel: Janssen, Merck, AstraZeneca. A.C. reports receiving honoraria from Regeneron, Bristol Myers Squibb. J.H.L. reports receiving grants: Lilly S.A.U, AstraZeneca. Honoraria from: AstraZeneca, Takeda, MSD Oncology, Astellas, Owkin, Amgen, ThermoFisher, Pfizer. Advisory board: AstraZeneca, Amgen, Janssen, Biocartis, Pfizer. Support for attending meetings and\/or travel: AstraZeneca, ThermoFisher, Pfizer, MSD Oncology. P.R. reports receiving honoraria from: Amgen, Daiichi Sankyo, Abbott. Consulting or or Advisory Role for: Daiichi Sankyo, IGES Pharma Travel. Acommodation Expenses from: AstraZeneca, Bristol Myers Squibb, Kyowa Kirin, MSD, PharmaMar, Roche. O.M. reports writing aid from Roche, speakers\u00b4 bureau from MSD Merck and Sharp, Janssen Pharmaceuticals, Pfizer, and Astra Zeneca, and travel aid from Takeda, and Recordati. A.M. reports receiving consulting fees from AstraZeneca\/Medimmune, Bristol-Meyers Squibb, F. Hoffmann-La Roche AG, Merck Sharp & Dohme, MSD Oncology, Pfizer. Honoraria from AstraZeneca\/Medimmune, Bristol-Myers Squibb, F. Hoffmann La Roche AG, Merck Sharp & Dohme, MSD Oncology, Pfizer, Amgen. Steering committee member: AstraZeneca\/Medimmune. Support for attending meetings and\/or travel: AstraZeneca\/Medimmune, Bristol-Myers Squibb, F. Hoffmann La Roche AG, Merck Sharp & Dohme, MSD Oncology, Pfizer, Lilly. None of these relationships are considered to have influenced the design, analysis, or interpretation of the current study. Other authors declare no conflicts of interest relevant to this publication, in accordance with editorial policies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}